Replies to post #483567 on NorthWest Biotherapeutics Inc (NWBO)

[flipper44]

It’s the one in bold below.

List of Anti-PD-1 monoclonal antibodies:

Keytruda
pembrolizumab

Opdivo (Pro)
Generic name: nivolumab


Libtayo (Pro)
Generic name: cemiplimab

Tecentriq (Pro)
Generic name: atezolizumab

Jemperli (Pro)
Generic name: dostarlimab

Imfinzi (Pro)
Generic name: durvalumab

Bavencio (Pro)
Generic name: avelumab

[exwannabe]

Is anyone familiar with this cancer treatment?

Dostarlimab is a CI, specifically a PD-1 blocker.

100% CR is fantastic. It was in patients with mismatch-repair deficiency though, and we already know those are very responsive to PD-(L)1 agents.

I doubt the CI is really much different from the other PD-1s. Same MOA.

Still a nice commercial win as that will be very pretty label.

[GPha]

My post gonna be partially irrelevant since ex answered your inquiry. I'm giving a piece of extra information for anyone who could benefit from it regarding the nomenclature of biologics specially targeted monoclonal antibodies, especially for oncology purposes.

If it contains substem "ci" then it's targeting the circulatory system for example Bevacizumab and Ramucirumab.
If the substem was "tu" then it targets the tumor examples are many here such as Cetuximab, Trastuzumab, Pertuzumab, Panitumumab, Inotuzumab, etc...
If the substem was "li" then it targets the immune system for example Ipilimumab, Nivolumab, Atezolizumab, and our friend Pembrolizumab.

Another information mab is the suffix that monoclonal antibodies share but the letters before it refers to the origin of the antibody itself. For xi (Infliximab)means the origin was the chimeric origin. While zu (Palivizumab) means it's of humanized origin. lastly, u (Golimumab) means it's from human origin.
by origin, we don't mean we take from a living human we modify the cells in long process not gonna get into the details of it.
hopefully, anyone can utilize this information to guide him through the world of biotech.

[biosectinvestor]

It’s a PD-1 inhibitor. Others may likely work similarly for this particular condition as well. It will be interesting to see if they do.

It’s great that this particular cancer, once it is unmasked by the drug, is so immunogenic.

The stories lack depth and are just filled with enthusiasm. Which is great. It’s a phenomenal application of just exactly the right technology to the right cancer. But Checkpoint Inhibitor (CI’s) do not do anything like that with every cancer they meet. Many will read these stories and unfortunately think there is 1 drug that melts all cancers. When really it’s a very exciting result for a very particular tumor type. Great example of how CI’s work. And hopefully the result also endures for good, and they do not get any later recurrence. Very exciting!